Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services
-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP conditional approval prior to FDA approval DUBLIN, Ireland , Sept.
View HTML
Toggle Summary Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences
DUBLIN, Ireland , Aug. 31, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming
View HTML
Toggle Summary Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
-SIVEXTRO ® adds revenue generating product creating additional scale and synergies- -Relaunch of XENLETA ® and SIVEXTRO planned with targeted in-person promotion- -Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc
View HTML
Toggle Summary Nabriva Therapeutics to Report Second Quarter 2020 Financial Results on August 6, 2020
DUBLIN, Ireland , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial
View HTML
Toggle Summary Nabriva Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
DUBLIN, Ireland , July 30, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder , Chief Executive Offer at
View HTML
Toggle Summary NABRIVA Receives European Approval for XENLETA® (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)
- XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years -XENLETA approval provides urgently needed short-course, empiric monotherapy treatment option for CAP aligned with core principles of antimicrobial stewardship DUBLIN , July 28, 2020
View HTML
Toggle Summary Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study
-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone -Nabriva awarded grant funding from the Austrian Research Promotion Agency to further characterize the anti-inflammatory and immunomodulatory properties of Lefamulin DUBLIN, Ireland , July 23, 2020 (GLOBE
View HTML
Toggle Summary XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia
-XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc. DUBLIN, Ireland , July 16, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to
View HTML
Toggle Summary Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.
Accretive transaction creates synergies and scale that strengthen Nabriva’s community-focused commercialization organization to optimize product uptake   Nabriva partners with Amplity Health to provide community-focused customer engagement and sales initiatives for SIVEXTRO and XENLETA ®
View HTML
Toggle Summary WEP Clinical Partners With Nabriva Therapeutics For The Named Patient Supply Of Xenleta® (Lefamulin)
WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) is designed to ensure that physicians, contingent on
View HTML

For Media Inquiries

E-mail: PR@nabriva.com


For Investor Relations

E-mail: IR@nabriva.com